All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results ConPlas-19, 2020 0.56 [0.20; 1.57]
DAWN-Plasma, 2021 0.61 [0.24; 1.55]
NCT04397757, 2021 0.47 [0.04; 5.45]
Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
0.82 [0.42 ; 1.61 ] ConPlas-19, 2020, DAWN-Plasma, 2021, NCT04397757, 2021, Sekine (PLACOVID), 2021 4 24% 1,072 moderate not evaluable death D28detailed results AlQahtani, 2020 0.47 [0.04; 5.69]
ASCOT, 2021 0.60 [0.06; 5.99]
Balcells, 2020 4.22 [0.33; 53.77]
Bennett-Guerrero, 2021 0.86 [0.24; 3.11]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
CONCOR-1, 2021 1.12 [0.86; 1.46]
ConPlas-19, 2020 0.49 [0.20; 1.19]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Kirenga, 2021 1.25 [0.46; 3.39]
Li, 2020 0.59 [0.22; 1.59]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Menichetti, 2021 0.75 [0.37; 1.53]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04528368, 2021 0.88 [0.02; 50.20]
O’Donnell, 2021 0.47 [0.21; 1.06]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
0.99 [0.93 ; 1.05 ] AlQahtani, 2020, ASCOT, 2021, Balcells, 2020, Bennett-Guerrero, 2021, Co-CLARITY, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COPLA-II trial, 2020, DAWN-Plasma, 2021, Kirenga, 2021, Li, 2020, LIFESAVER, 2021, Menichetti, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04528368, 2021, O’Donnell, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, RECOVER, 2021, RECOVERY (plasma), 2021, Sekine (PLACOVID), 2021 25 0% 16,724 moderate critical deathsdetailed results AlQahtani, 2020 0.47 [0.04; 5.69]
ASCOT, 2021 0.60 [0.06; 5.99]
Balcells, 2020 3.26 [0.62; 17.12]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CAPSID, 2021 0.84 [0.28; 2.50]
CCAP-2, 2021 2.03 [0.61; 6.77]
Co-CLARITY, 2021 0.92 [0.02; 50.28]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConCOVID (Gharbharan et al.), 2020 0.95 [0.20; 4.59]
CONFIDENT, 2020 0.84 [0.52; 1.37]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CONTAIN COVID-19, 2021 0.86 [0.60; 1.25]
COP-COVID-19, 2021 0.96 [0.36; 2.56]
COPLA-II trial, 2020 1.17 [0.72; 1.92]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
Holm K, 2021 0.49 [0.08; 2.89]
Kirenga, 2021 1.25 [0.46; 3.39]
Li, 2020 0.59 [0.22; 1.59]
Libster, 2020 0.50 [0.09; 2.71]
LIFESAVER, 2021 2.00 [0.16; 24.66]
Menichetti, 2021 0.75 [0.37; 1.53]
NCT04385199, 2021 0.75 [0.15; 3.77]
NCT04397757, 2021 0.15 [0.03; 0.75]
NCT04403477 (two doses), 2021 0.53 [0.14; 2.01]
NCT04442191, 2021 0.11 [0.00; 143.68]
NCT04528368, 2021 0.88 [0.02; 50.20]
O’Donnell, 2021 0.47 [0.21; 1.06]
PC/COVID-19, 2021 0.63 [0.11; 3.58]
PERUCONPLASMA, 2021 0.36 [0.04; 3.13]
PlasmAr, 2020 0.93 [0.47; 1.85]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Rasheed, 2020 0.13 [0.01; 1.09]
RECOVER, 2021 1.09 [0.38; 3.13]
RECOVERY (plasma), 2021 1.00 [0.93; 1.07]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
0.98 [0.92 ; 1.04 ] AlQahtani, 2020, ASCOT, 2021, Balcells, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CAPSID, 2021, CCAP-2, 2021, Co-CLARITY, 2021, CONCOR-1, 2021, ConCOVID (Gharbharan et al.), 2020, CONFIDENT, 2020, ConPlas-19, 2020, CONTAIN COVID-19, 2021, COP-COVID-19, 2021, COPLA-II trial, 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, Holm K, 2021, Kirenga, 2021, Li, 2020, Libster, 2020, LIFESAVER, 2021, Menichetti, 2021, NCT04385199, 2021, NCT04397757, 2021, NCT04403477 (two doses), 2021, NCT04442191, 2021, NCT04528368, 2021, O’Donnell, 2021, PC/COVID-19, 2021, PERUCONPLASMA, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Rasheed, 2020, RECOVER, 2021, RECOVERY (plasma), 2021, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021 38 0% 19,932 moderate critical deaths (time to event analysis only)detailed results Balcells, 2020 3.26 [0.62; 17.12]
Baldeon, 2022 1.85 [0.49; 6.97]
Bennett-Guerrero, 2021 0.80 [0.26; 2.45]
CONCOR-1, 2021 1.02 [0.77; 1.36]
ConPlas-19, 2020 0.46 [0.19; 1.15]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
DAWN-Plasma, 2021 0.99 [0.52; 1.88]
PlasmAr, 2020 0.93 [0.47; 1.85]
1.01 [0.77 ; 1.32 ] Balcells, 2020, Baldeon, 2022, Bennett-Guerrero, 2021, CONCOR-1, 2021, ConPlas-19, 2020, CP-COVID-19, 2021, DAWN-Plasma, 2021, PlasmAr, 2020 8 9% 2,497 moderate not evaluable clinical deteriorationdetailed results Balcells, 2020 1.46 [0.44; 4.81]
CAPSID, 2021 0.63 [0.29; 1.40]
ConPlas-19, 2020 1.00 [0.65; 1.53]
CONTAIN COVID-19, 2021 0.94 [0.75; 1.18]
Kirenga, 2021 0.91 [0.38; 2.17]
Libster, 2020 0.52 [0.29; 0.94]
0.89 [0.74 ; 1.06 ] Balcells, 2020, CAPSID, 2021, ConPlas-19, 2020, CONTAIN COVID-19, 2021, Kirenga, 2021, Libster, 2020 6 1% 1,415 moderate not evaluable clinical improvementdetailed results Balcells, 2020 0.91 [0.52; 1.60]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
CAPSID, 2021 1.58 [0.71; 3.49]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Li, 2020 1.40 [0.79; 2.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 0.81 [0.50; 1.31]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
1.07 [0.87 ; 1.31 ] Balcells, 2020, Bennett-Guerrero, 2021, CAPSID, 2021, ConPlas-19, 2020, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, Sekine (PLACOVID), 2021 9 31% 1,197 moderate not evaluable clinical improvement (14-day)detailed results Li, 2020 2.27 [0.90; 5.72]
2.27 [0.90 ; 5.72 ] Li, 2020 1 0% 103 NA not evaluable clinical improvement (28-day)detailed results Bennett-Guerrero, 2021 1.02 [0.25; 4.20]
Li, 2020 1.42 [0.65; 3.10]
O’Donnell, 2021 1.38 [0.73; 2.61]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
1.33 [0.83 ; 2.14 ] Bennett-Guerrero, 2021, Li, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021 5 53% 620 moderate not evaluable clinical improvement (7-day)detailed results Li, 2020 0.98 [0.27; 3.58]
0.98 [0.27 ; 3.58 ] Li, 2020 1 0% 103 NA not evaluable clinical improvement (time to event analysis only)detailed results Balcells, 2020 0.91 [0.52; 1.60]
Bennett-Guerrero, 2021 0.75 [0.21; 2.68]
ConPlas-19, 2020 0.95 [0.60; 1.52]
Li, 2020 1.40 [0.79; 2.49]
O’Donnell, 2021 1.20 [0.87; 1.65]
PlasmAr, 2020 1.00 [0.76; 1.32]
1.06 [0.90 ; 1.26 ] Balcells, 2020, Bennett-Guerrero, 2021, ConPlas-19, 2020, Li, 2020, O’Donnell, 2021, PlasmAr, 2020 6 0% 873 low not evaluable death or ventilationdetailed results Balcells, 2020 0.67 [0.14; 3.26]
CONCOR-1, 2021 1.16 [0.94; 1.43]
ConPlas-19, 2020 0.94 [0.86; 1.02]
DAWN-Plasma, 2021 1.01 [0.64; 1.59]
Menichetti, 2021 0.88 [0.59; 1.32]
RECOVERY (plasma), 2021 0.99 [0.93; 1.05]
0.98 [0.93 ; 1.03 ] Balcells, 2020, CONCOR-1, 2021, ConPlas-19, 2020, DAWN-Plasma, 2021, Menichetti, 2021, RECOVERY (plasma), 2021 6 0% 13,240 moderate not evaluable hospital dischargedetailed results ConPlas-19, 2020 1.02 [0.82; 1.28]
DAWN-Plasma, 2021 1.06 [0.87; 1.30]
RECOVERY (plasma), 2021 0.99 [0.92; 1.07]
1.00 [0.94 ; 1.07 ] ConPlas-19, 2020, DAWN-Plasma, 2021, RECOVERY (plasma), 2021 3 0% 12,391 moderate not evaluable mechanical ventilationdetailed results AlQahtani, 2020 0.67 [0.22; 2.02]
Balcells, 2020 2.98 [0.41; 21.61]
COPLA-II trial, 2020 0.58 [0.37; 0.92]
Holm K, 2021 0.39 [0.01; 12.68]
NCT04397757, 2021 0.41 [0.13; 1.35]
O’Donnell, 2021 1.50 [0.47; 4.82]
PlasmAr, 2020 0.86 [0.39; 1.93]
RECOVERY (plasma), 2021 0.98 [0.88; 1.09]
0.85 [0.65 ; 1.10 ] AlQahtani, 2020, Balcells, 2020, COPLA-II trial, 2020, Holm K, 2021, NCT04397757, 2021, O’Donnell, 2021, PlasmAr, 2020, RECOVERY (plasma), 2021 8 23% 12,047 moderate not evaluable mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
DAWN-Plasma, 2021 1.08 [0.65; 1.80]
0.97 [0.62 ; 1.52 ] CP-COVID-19, 2021, DAWN-Plasma, 2021 2 0% 583 moderate not evaluable viral clearance detailed results Balcells, 2020 2.66 [0.69; 10.20]
CP-COVID-19, 2021 1.12 [0.16; 7.84]
Salman, 2020 1.00 [0.02; 53.89]
1.91 [0.66 ; 5.55 ] Balcells, 2020, CP-COVID-19, 2021, Salman, 2020 3 0% 177 low not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 1.51 [0.33; 6.94]
Kirenga, 2021 0.95 [0.76; 1.19]
0.96 [0.77 ; 1.20 ] CP-COVID-19, 2021, Kirenga, 2021 2 0% 225 moderate not evaluable viral clearance by day 7detailed results Balcells, 2020 2.66 [0.69; 10.20]
Kirenga, 2021 0.87 [0.65; 1.16]
Salman, 2020 1.00 [0.02; 53.89]
1.07 [0.56 ; 2.05 ] Balcells, 2020, Kirenga, 2021, Salman, 2020 3 21% 205 moderate not evaluable ICU admissiondetailed results CP-COVID-19, 2021 0.82 [0.35; 1.91]
Libster, 2020 0.33 [0.07; 1.58]
0.67 [0.32 ; 1.41 ] CP-COVID-19, 2021, Libster, 2020 2 1% 260 moderate not evaluable serious adverse eventsdetailed results Balcells, 2020 4.54 [0.20; 105.23]
CONCOR-1, 2021 1.27 [1.02; 1.58]
ConPlas-19, 2020 0.89 [0.43; 1.86]
O’Donnell, 2021 0.64 [0.35; 1.17]
PlasmAr, 2020 1.40 [0.78; 2.51]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
1.19 [0.95 ; 1.50 ] Balcells, 2020, CONCOR-1, 2021, ConPlas-19, 2020, O’Donnell, 2021, PlasmAr, 2020, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021 7 38% 4,022 moderate not evaluable adverse eventsdetailed results Kirenga, 2021 1.13 [0.50; 2.58]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
1.08 [0.86 ; 1.37 ] Kirenga, 2021, Sekine (PLACOVID), 2021 2 0% 296 moderate not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-28 13:11 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290